Zai Lab’s Zocilurtatug Pelitecan (Zoci, Formerly ZL-1310) Demonstrates High Response Rates, Encouraging Durability and Well-Tolerated Safety Profile in First-Line Extensive-Stage Small Cell Lung Cancer
Zai Lab reported Phase 1b data for its DLL3-targeting ADC zocilurtatug pelitecan (zoci) plus atezolizumab in first-line extensive-stage small cell lung cancer, showing a confirmed ORR of 81.8% and a 6-month PFS rate of 81.9% at the recommended Phase 3 dose. The chemotherapy-free doublet was well tolerated, with only 9.1% Grade ≥3 treatment-related AEs and no treatment-related discontinuations — favorable versus the current standard of care's ~60% rate of Grade >3 AEs and ~5-month mPFS.
Key figures
- Drug Name
- zocilurtatug pelitecan (zoci, formerly ZL-1310)
- Phase Of Trial
- Phase 1b (Phase 3 planned)
- Orr doublet
- 81.8% (27/33)
- Orr triplet
- 92.3%
- Mdor triplet
- 7.7 months
- Mpfs triplet
- 8.4 months
- Phase3 initiation
- by year-end 2026
- Six month pfs rate
- 81.9%
- Grade3plus related aes
- 9.1% (3/33)
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.